Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer. | EBSCOhost

Connecting you to content on EBSCOhost

Title: Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer.
Authors: Ding, Yue; Ye, Zheng; Ding, Bo; Feng, Songwei; Zhang, Yang; Shen, Yang
Publication: Molecular Biotechnology, 2025, Vol 67, Issue 6, p2428
ISSN: 1073-6085
Publication type: Academic Journal
DOI: 10.1007/s12033-024-01207-5